Year: 2021

– Otenaproxesul’s acute pain clinical program set to begin early next quarter – Ended quarter with a $60 million cash position TORONTO, CANADA — (November 16, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has filed … Continued

– Leverages existing extensive clinical data to shorten development path – Acute pain clinical program initiating early next quarter – Third-party commercial studies underway TORONTO, CANADA — (November 1, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide … Continued

TORONTO, CANADA — (October 14, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, is pleased to provide an update following a full scientific and strategic review involving external experts and key opinion leaders. … Continued

 TORONTO, CANADA — (September 8, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13 – … Continued

TORONTO, CANADA — (August 19, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information … Continued

– Ended quarter with a strong $67 million cash position – AME study on required pause; data expected in October TORONTO, CANADA — (August 17, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has filed its … Continued

TORONTO, CANADA — (August 9, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10 – 12. … Continued

– Current AME study paused in adherence to safety protocol  TORONTO, CANADA — (August 3, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has placed its absorption, metabolism and excretion (“AME”) study of otenaproxesul on a … Continued

– Phase III preparations proceeding well; AME study underway – New IP in development to expand indications and bolster existing pipeline – Potential listing on senior U.S. exchange synchronized with first Phase III trial TORONTO, CANADA – (July 27, 2021) To our shareholders, Our achievements in the last twelve months have set the stage for … Continued

– Phase III-enabling activities for otenaproxesul proceeding well; AME study begins next week – Ended year with a strong $72 million cash position, providing over two years of runway and fully funding Phase III adaptive trial  TORONTO, CANADA — (June 28, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging … Continued

– Enables rapid advancement of multiple drug discovery programs to exploit hydrogen sulfide platform in new disease areas TORONTO, CANADA — (June 25, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to target inflammation in a wide range of health … Continued

TORONTO, CANADA — (June 7, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the following U.S.-based virtual investor conferences in June: 2021 LD Micro Invitational XI, Live company … Continued

 NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (June 3, 2021) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX:ATE) is pleased to announce that, further to its press release dated May 7, 2021, the Company has completed its previously announced amalgamation transaction (the “Transaction”) to … Continued

– Amalgamation secures 100% ownership of IP underlying Antibe’s pipeline – Strengthens position in large-market partnering discussions  TORONTO, CANADA — (May 7, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (“Antibe” or the “Company”), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory … Continued

TORONTO, CANADA — (April 14, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for inflammation arising from a wide range of medical conditions, is pleased to announce its participation in the Bloom Burton & Co. Healthcare Investor Conference being held … Continued

– Enables expansion to U.S.-based clinical trials, advances preparation for Phase III program TORONTO, CANADA — (March 29, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for inflammation arising from a wide range of medical conditions, today announced that the … Continued

TORONTO, CANADA — (March 3, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions, today announced its participation in the following investor conferences in March: H.C. Wainwright Global Life … Continued

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO — (February 24, 2021) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX:ATE) today announced that it has closed its previously announced bought deal public offering of 6,727,500 units (the “Offered Securities”) in the capital of the Company at a … Continued

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (February 17, 2021) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX:ATE) today announced that it has entered into an agreement with Canaccord Genuity Corp. on behalf of a syndicate of underwriters (together, the “Underwriters”) and pursuant to … Continued

TORONTO, CANADA — (February 12, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today filed its financial and operating results for the fiscal quarter ended December 31, 2020. “We had a busy quarter and made excellent … Continued

– US$100 million in milestone payments including US$20 million upfront, as well as a double-digit royalty – Nuance’s business model, commercial acumen and collaborative approach considered an ideal fit for Antibe   TORONTO, CANADA — (February 9, 2021) – Antibe Therapeutics Inc. — (TSX: ATE, OTCQB: ATBPF) today announced that it has licensed otenaproxesul to Nuance … Continued

 – Large market partnering program now underway – – Limited COVID-19 impact: Phase III program slated to start in second half of 2021 – – U.S. institutional outreach expanding –  TORONTO, CANADA — (January 11, 2021) To our shareholders, As we build on last year’s significant clinical and capital markets achievements and enter the homestretch in … Continued

– Dr. Haut spearheaded AskBio’s recent $4 billion acquisition by Bayer AG –   TORONTO, CANADA — (January 7, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Dr. Don Haut to … Continued